Fosamprenavir treatment in a highly active antiretroviral therapy schedule induces a HCV-RNA decrease and a Th1...

Area of Science:

• Immunology
• Virology
• Hepatology

Background:

• HIV/HCV co-infection presents complex challenges for immune reconstitution and treatment efficacy.
• Evaluating the impact of antiretroviral therapy on host immune responses in co-infected patients is crucial.

Purpose of the Study:

• To assess the immunological and virological response to HAART including fosamprenavir in treatment-naïve HIV/HCV co-infected patients.
• To investigate the effect of this regimen on T-cell profiles, cytokine responses, viral loads, and liver enzymes.

Main Methods:

• Ten treatment-naïve HIV/HCV co-infected patients received a HAART regimen including zidovudine, lamivudine, fosamprenavir, and ritonavir.
• Measurements included CD4+ T cells, HCV-specific interferon-gamma (IFN-γ) and interleukin-4 (IL-4) responses, HIV-RNA, HCV-RNA, and transaminases at baseline and at 1, 3, and 6 months.

Main Results:

• Significant reductions in HIV-RNA, HCV-RNA, and transaminases were observed at 1 and 3 months.
• Treatment led to increased CD4+ T cell counts and enhanced HCV-specific IFN-γ responses, alongside decreased IL-4 levels.
• By 6 months, all patients had normalized transaminase levels, though only 40% achieved undetectable HCV-RNA.

Conclusions:

• HAART including fosamprenavir can modulate the immune system, promoting a Th1-biased response in HIV/HCV co-infected individuals.
• Fosamprenavir-containing regimens may offer therapeutic potential for chronic hepatitis C in the context of HIV co-infection.
• Larger studies are warranted to confirm these findings and explore long-term implications.